What is Metabolic Solutions Development?
Metabolic Solutions Development Company (MSDC) operates at the intersection of advanced pharmacology and metabolic health. The organization specializes in the identification and development of novel therapeutic agents designed to address the underlying mechanisms of age-related mitochondrial dysfunction. By targeting the root causes of insulin resistance and type 2 diabetes, MSDC has established a specialized pipeline featuring investigational assets such as MSDC-0160 and MSDC-0602. Their market position is defined by a commitment to precision medicine, aiming to transform the standard of care for patients suffering from chronic metabolic conditions through rigorous scientific inquiry and drug development excellence.
How much funding has Metabolic Solutions Development raised?
Metabolic Solutions Development has raised a total of $12.9M across 2 funding rounds:
Grant
$1.1M
Debt
$11.8M
Grant (2011): $1.1M, investors not publicly disclosed
Debt (2012): $11.8M, investors not publicly disclosed
Key Investors in Metabolic Solutions Development
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Metabolic Solutions Development?
With the recent influx of capital, Metabolic Solutions Development is poised to transition into a more aggressive phase of clinical development. The strategic focus will likely shift toward scaling the manufacturing and testing of its lead candidates, MSDC-0160 and MSDC-0602, to meet regulatory requirements and prepare for potential commercialization. As the company navigates the complexities of late-stage drug development, the emphasis will remain on demonstrating efficacy in human trials and securing the necessary data to validate their therapeutic approach. This enterprise-level backing provides the runway required to sustain long-term research cycles, ensuring that the firm remains a competitive force in the global metabolic disease market.
See full Metabolic Solutions Development company page
